Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Eton Pharmaceuticals (Nasdaq: ETON), a company focused on rare disease treatments, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company's CEO, Sean Brynjelsen, will deliver a presentation that will be available on demand starting September 9, 2024, at 7am ET.
Investors can access the presentation online, and those interested in in-person meetings with the company are encouraged to contact H.C. Wainwright's Corporate Access team. This event provides Eton Pharmaceuticals with an opportunity to showcase its innovative approach to developing and commercializing treatments for rare diseases to a global investment audience.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda specializzata in trattamenti per malattie rare, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright a New York. L'amministratore delegato dell'azienda, Sean Brynjelsen, presenterà un intervento che sarà disponibile on demand a partire da 9 settembre 2024, alle 7:00 ET.
Gli investitori possono accedere alla presentazione online e coloro che sono interessati a incontri di persona con l'azienda sono invitati a contattare il team Corporate Access di H.C. Wainwright. Questo evento offre a Eton Pharmaceuticals l'opportunità di mostrare il suo approccio innovativo nello sviluppo e nella commercializzazione di trattamenti per malattie rare a un pubblico di investitori globali.
Eton Pharmaceuticals (Nasdaq: ETON), una empresa enfocada en tratamientos para enfermedades raras, anunció su participación en la 26ª Conferencia Global de Inversiones Anual de H.C. Wainwright en la ciudad de Nueva York. El CEO de la empresa, Sean Brynjelsen, realizará una presentación que estará disponible bajo demanda a partir del 9 de septiembre de 2024, a las 7 a.m. ET.
Los inversores pueden acceder a la presentación en línea y aquellos interesados en reuniones en persona con la empresa son alentados a contactar al equipo de Corporate Access de H.C. Wainwright. Este evento brinda a Eton Pharmaceuticals la oportunidad de mostrar su enfoque innovador para desarrollar y comercializar tratamientos para enfermedades raras ante una audiencia de inversionistas global.
Eton Pharmaceuticals (Nasdaq: ETON), 희귀질환 치료에 집중하는 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Sean Brynjelsen이 2024년 9월 9일 오전 7시 ET부터 주문형으로 제공될 발표를 할 예정입니다.
투자자들은 온라인으로 발표에 접근할 수 있으며, 회사와의 대면 회의에 관심이 있는 분들은 H.C. Wainwright의 Corporate Access 팀에 연락해 주시기 바랍니다. 이 이벤트는 Eton Pharmaceuticals에게 희귀질환 치료 개발 및 상용화에 대한 혁신적인 접근 방식을 글로벌 투자자들에게 선보일 수 있는 기회를 제공합니다.
Eton Pharmaceuticals (Nasdaq: ETON), une entreprise axée sur les traitements des maladies rares, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright à New York. Le PDG de l'entreprise, Sean Brynjelsen, donnera une présentation qui sera disponible à la demande à partir du 9 septembre 2024, à 7 heures ET.
Les investisseurs peuvent accéder à la présentation en ligne, et ceux intéressés par des réunions en personne avec l'entreprise sont encouragés à contacter l'équipe Corporate Access de H.C. Wainwright. Cet événement offre à Eton Pharmaceuticals l'occasion de mettre en avant son approche innovante en matière de développement et de commercialisation de traitements pour maladies rares devant un public d'investisseurs mondial.
Eton Pharmaceuticals (Nasdaq: ETON), ein Unternehmen, das sich auf Behandlungen seltener Krankheiten konzentriert, kündigte seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York City an. Der CEO des Unternehmens, Sean Brynjelsen, wird eine Präsentation halten, die ab 9. September 2024, um 7 Uhr ET auf Abruf verfügbar sein wird.
Investoren können die Präsentation online abrufen, und Interessierte an persönlichen Treffen mit dem Unternehmen werden ermutigt, das Corporate Access-Team von H.C. Wainwright zu kontaktieren. Diese Veranstaltung bietet Eton Pharmaceuticals die Möglichkeit, ihr innovatives Konzept zur Entwicklung und Vermarktung von Behandlungen für seltene Krankheiten einem globalen Investorenpublikum vorzustellen.
- None.
- None.
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
The Company’s presentation by Sean Brynjelsen, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7am ET.
Investors can access the presentation here.
To schedule an in-person 1x1 meeting with the Company, please contact Corporate Access at H.C. Wainwright.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
FAQ
When is Eton Pharmaceuticals (ETON) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Eton Pharmaceuticals (ETON) at the H.C. Wainwright conference?
How can investors access Eton Pharmaceuticals' (ETON) presentation at the H.C. Wainwright conference?
Where is the H.C. Wainwright Global Investment Conference being held in 2024?
What is the focus of Eton Pharmaceuticals' (ETON) business?
